EP0353262A1 - New therapeutical use of h 2?-receptor-blocking compounds - Google Patents

New therapeutical use of h 2?-receptor-blocking compounds

Info

Publication number
EP0353262A1
EP0353262A1 EP88910155A EP88910155A EP0353262A1 EP 0353262 A1 EP0353262 A1 EP 0353262A1 EP 88910155 A EP88910155 A EP 88910155A EP 88910155 A EP88910155 A EP 88910155A EP 0353262 A1 EP0353262 A1 EP 0353262A1
Authority
EP
European Patent Office
Prior art keywords
treatment
receptor
compound
bone
blocking compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP88910155A
Other languages
German (de)
French (fr)
Inventor
Rolf H Kanson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hassle AB
Original Assignee
Hassle AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hassle AB filed Critical Hassle AB
Publication of EP0353262A1 publication Critical patent/EP0353262A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones

Definitions

  • the present invention is related to a novel method for the treatment of several bone affecting diseases, especially osteoporosis, which are characterized by loss of bone mass.
  • bone formation which is associated with the number and activity of osteoblasts, that is cells associated with the production of bone in the organism
  • bone loss which is associated with the number and activity of osteoclasts, that is cells associated with the absorption and removal of bone
  • osteoporosis can be mentioned, Paget's disease of bone, hyperparathyroidism and related disorders, and several malignant neoplasms where tumor cells are producing osteoclast-activating factors and cause hypercalcemia.
  • osteoporosis bone formation as well as bone resorption are disturbed, resulting in loss of bone tissue, decreased bone mass, and bone fragility. Osteoporosis predominantly affects the elderly, but also other groups such as po ⁇ _menopausal women, where an estrogen deficit is believed re be a significant etiological factor, and immobilized patients. At this point it is not possible to clear up the whole picture of the disease mechanism and estimate which is the primary cause of osteoporosis. However, about 25% of osteoporotic females belong to what is called "rapid bone losers" and at least in those patients the bone resorption rate is probably increased.
  • Landry and Fleisch showed in immobilization induced osteoporosis that bone resorption rate was accelerated, (Landry, M. and Fleisch, H.: The influence of immobilization on bone formation as evaluated the incorporation of tetracyclines. J. Bone Joint Surg. 46B:764, 1964).
  • osteoporosis comprise fractures, especially hip fractures, but also vertebral fractures and fractures of the proximal radius, and complication of such fractures.
  • the present methods for the treatment of osteoporosis include exercise? administration of estrogen, especially for postmenopausal women; and consumption of calcium or calcium containing material such as milk. Calcitonin, a hormone associated with calcium metabolism, has also been used in the treatment of osteoporosis.
  • malignant tumors are known to be associated by hypercalcemia which is due to increased osteoclastic activity. This is a common complication for instance in the case of breast cancer and prcstats cancer which are both one of the most common malignant tumors. Hypercalcemia is due to both systemic and local factors .
  • Some malignant cells are known to secrete agents which stimulate bone resorption (Sato, K,; Fujii, Y., Kachivehi, T., Kasono, K., Shizume, K. : Production of interleukin 1 alpha (IL-1 ⁇ )-like activity and colony stimulating activity by clonal sguanous cell carcinomas derived from patients with hypercalcemia and leucocytosis. In: Calcium Regulation and Bone Metabolism Vol. 9 (eds. D.V. Cohu, T.J. Martin, P.J. Meunier), 1986).
  • Paget's disease (or osteitis deformans) of bone is a disease of unknown etiology where bone resorption and remodelling are increased leading sometimes even to the fractures of affected bone. Bone pain is the main indication of treatment in these patients. In these patients there is highly elevated local osteoclastic bone destruction. The incidence of osteitis deformans is vey low in Scandinavian countries. In England it has been estimated to be present in 3-4% of population on the basis of autopsy studies (Anderson's Textbook of Pathology 1986). It is very rare in patients under 40 years. Calcitonin and diphosphonates are also used in the treatment of Paget's disease.
  • H 2 -receptor-blocking agents are useful as prophylactic and therapeutic agents for the treatment of osteoporosis; Paget's disease of bone; hyperparathyroidism, both primary and secondary; malignant neoplasms where tumor cells are producing osteoclast- activating factors and cause hypercalcinemia; immobilization-induced osteoporosis; parodontal diseases; and prostetic and implant-related bone losses.
  • H 2 -receptor-blocking agents examples include:
  • the preferred H 2 -blocking agents are cimetidine and ranitidine.
  • the invention relates to
  • a pharmaceutical preparation for use in the prophylactic and therapeutic treatment of each of the ailments above comprising a H 2 -receptor-blocking agent as active ingredient
  • a H 2 -receptor-blocking agent for use in the manufacture of a medicament for the prophylactic and therapeutic treatment of each of the ailments above.
  • a method for improving the healing rate of bone fractures by administering to a host in need thereof of an effective amount of a H 2 -receptor -blocking agent.
  • Sprague-Dawley male rats (Alab, Sweden) weighing 175-200 g before the tests were used. They obtained a standard diet consisting of rat feed pellets (Alab, Swiss, Sweden) and tap water.
  • Nine rats were given ranitidine (Hassle, Sweden) 1700 ⁇ mol/kg x day, approximately 600 mg/kg body weight per day) via osmotic mini pumps (Alzet 2ML2) which had been implanted subcutaneously.
  • the rats were treated during 26 days and mini pumps were exchanged after 14 days. The pumps were placed under the abdominal skin. Seven rats were used as untreated controls.
  • Serum was prepared at the blood tapping from each rat and gastrin was determined by radioimmunoanalysis (Stadil, F. & Rehfeld, J.F. (1973) Determination of gastrin in Serum. An evaluation of the reliability of a radioimmunoassay. Scan. J. Gastroent. 8, 101-112; Hakansson, R. , Kroesen, J.H. Liedberg, G., Oscarson, J., Rehfeld, J.E.. & Stadil, F. (1974) Correlation between serum gastrin concentration and rat stomach histidine decarboxylase activity, J. Physiol. 243, 483-498).
  • Gastrectomia was prepared by resection of the stomach followed by suturation of eosophagus and duodenum end to end. Operated animals were allowed to recover for one week before treatment with the test substance, as has been described in "Pharmacological tests". The test results are given in Fig. 1 and Fig. 2.
  • Fig.l shows the concentration of gastrin expressed as picogram/ml serum with untreated control rats (average of 7 rats, and with ranitidir-e-treated rats (average of 9 rats) after treatment for 26 days.
  • Fig. 2 shows the amount of radioactive calcium which has been incorporated into the skeleton (radius respectively sternum) expressed in cpm/mg bone ashes.
  • E shows the average of 7 control rats
  • F shows the average of 9 ranitidine-treated rats
  • G shows the average of 7 control rats
  • H shows the average of 9 ranitidine-treated rats.
  • the continuous lines represent the average of given number of rats and the dashed lines represent the standard error of the average value.
  • Ih ⁇ pharmaceutical formulation contains a compound of the invention in combination with a pharmaceutically acceptable carrier.
  • the carrier may be in the form of a solid, semi- solid or liquid diluent, or a capsule.
  • These pharmaceutical preparations are a further object of the invention.
  • the amount of active compounds is between 0.1-95 % by weight of the preparation, between 0.2-20 % by weight in preparations for parenteral use and between 1 and 50 % by weight in preparations for oral administration.
  • the typical daily dose of the active substance varies within a wide range and will depend on various factors such as for example the individual requirement of each patient, the route of administration and the disease. In general, oral and parenteral dosages will be in the range of 5 to 2000 mg per day of active substance.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un procédé pour traiter l'ostéoporose, la maladie osseuse de Paget, l'hyperparathyroïdisme, les néoplasmes malins provoquant l'hypercalcémie, les affections parodontales et les pertes osseuses protétiques et liées aux implants, consiste à administrer à un patient qui en est atteint, une quantité d'un composé de blocage des récepteurs de H2, ou son sel pharmaceutiquement acceptable. Sont également décrits des composés de blocage des récepteurs de H2 destinés à être utilisés dans la fabrication d'un médicament pour de telles maladies, ainsi que des préparations pharmaceutiques renfermant un composé de blocage des récepteurs de H2 destiné à être utilisé dans le traitement desdites maladies. Les composés préférés sont la cimétidine et la ranitidine.A method of treating osteoporosis, Paget's disease of the bone, hyperparathyroidism, malignant neoplasms causing hypercalcemia, periodontal disease, and bone and protein and implant-related loss is to administer to a patient suffering therefrom, an amount of an H2 receptor blocking compound, or its pharmaceutically acceptable salt. Also disclosed are H2 receptor blocking compounds for use in the manufacture of a medicament for such diseases, as well as pharmaceutical preparations containing an H2 receptor blocking compound for use in the treatment of said diseases . The preferred compounds are cimetidine and ranitidine.

Description

New therapeutical use of HL-receptor-blocking compounds
Field of the Invention
The present invention is related to a novel method for the treatment of several bone affecting diseases, especially osteoporosis, which are characterized by loss of bone mass.
Background of the Invention
The balance in normal subjects between on the one hand bone formation, which is associated with the number and activity of osteoblasts, that is cells associated with the production of bone in the organism, and on the other hand bone loss, which is associated with the number and activity of osteoclasts, that is cells associated with the absorption and removal of bone, is disturbed in several bone affecting diseases. At the present time there is no good treatment for any of these diseases, among which can be mentioned osteoporosis, Paget's disease of bone, hyperparathyroidism and related disorders, and several malignant neoplasms where tumor cells are producing osteoclast-activating factors and cause hypercalcemia.
Worldwide the most urgent need is for the treatment of osteoporosis and tumor associated hypercalcemia. In some areas, e.g. in England and in some other parts of Europe there is also high incidence of Paget's disease of bone.
In osteoporosis bone formation as well as bone resorption are disturbed, resulting in loss of bone tissue, decreased bone mass, and bone fragility. Osteoporosis predominantly affects the elderly, but also other groups such as poε_menopausal women, where an estrogen deficit is believed re be a significant etiological factor, and immobilized patients. At this point it is not possible to clear up the whole picture of the disease mechanism and estimate which is the primary cause of osteoporosis. However, about 25% of osteoporotic females belong to what is called "rapid bone losers" and at least in those patients the bone resorption rate is probably increased. Landry and Fleisch showed in immobilization induced osteoporosis that bone resorption rate was accelerated, (Landry, M. and Fleisch, H.: The influence of immobilization on bone formation as evaluated the incorporation of tetracyclines. J. Bone Joint Surg. 46B:764, 1964).
The clinical manifestations of osteoporosis comprise fractures, especially hip fractures, but also vertebral fractures and fractures of the proximal radius, and complication of such fractures.
In Finland it has been estimated that about 10% of all surgical hospital beds are used for the treatment of osteoporosis related fractures (Lϋthje, P.: Reisiluunkaulan ja trokantterin murtumapotilaiden hoito ja ennuste seka hiodon kustannukset. Thesis. Helsinki 1983).
The present methods for the treatment of osteoporosis include exercise? administration of estrogen, especially for postmenopausal women; and consumption of calcium or calcium containing material such as milk. Calcitonin, a hormone associated with calcium metabolism, has also been used in the treatment of osteoporosis.
Several malignant tumors are known to be associated by hypercalcemia which is due to increased osteoclastic activity. This is a common complication for instance in the case of breast cancer and prcstats cancer which are both one of the most common malignant tumors. Hypercalcemia is due to both systemic and local factors . Some malignant cells are known to secrete agents which stimulate bone resorption (Sato, K,; Fujii, Y., Kachivehi, T., Kasono, K., Shizume, K. : Production of interleukin 1 alpha (IL-1α)-like activity and colony stimulating activity by clonal sguanous cell carcinomas derived from patients with hypercalcemia and leucocytosis. In: Calcium Regulation and Bone Metabolism Vol. 9 (eds. D.V. Cohu, T.J. Martin, P.J. Meunier), 1986).
In malignant hypercalcemia calcitonin and diphosphonate treatment has been used.
Paget's disease (or osteitis deformans) of bone is a disease of unknown etiology where bone resorption and remodelling are increased leading sometimes even to the fractures of affected bone. Bone pain is the main indication of treatment in these patients. In these patients there is highly elevated local osteoclastic bone destruction. The incidence of osteitis deformans is vey low in Scandinavian countries. In England it has been estimated to be present in 3-4% of population on the basis of autopsy studies (Anderson's Textbook of Pathology 1986). It is very rare in patients under 40 years. Calcitonin and diphosphonates are also used in the treatment of Paget's disease.
Other disease states for the treatment of which antagonists to osteoclastic activity might be useful, are parodontal diseases and prostetic and implant bone losses.
It is an object of the present invention to provide compounds which by affecting the balance between osteoblast and osteoclast activity can be useful for prophylactic and therapeutic treatment of diseases as indicated above which are associated with bone loss. It is believed that the use of these compounds will also ultimately result in an increase of the bone mass. Outline of the Invention
According to the present invention it has been found that the class of compounds known as H2-receptor-blocking agents, as well as pharmaceutically acceptable salts thereof, are useful as prophylactic and therapeutic agents for the treatment of osteoporosis; Paget's disease of bone; hyperparathyroidism, both primary and secondary; malignant neoplasms where tumor cells are producing osteoclast- activating factors and cause hypercalcinemia; immobilization-induced osteoporosis; parodontal diseases; and prostetic and implant-related bone losses.
Examples of H2-receptor-blocking agents are:
Cimetidine
2-cyano-1-methyl-3-[2-[[5-methylimidazole-4-yl)-methyl]- thio]ethyl]guanidine
Ranitidine
N-[2-[[5-[(dimethylamino)methyl]furfuryl]thio]-ethyl]-N1- methyl-2-nitro-1,1-ethene-diamine
Famotidine
3- [ [ [ [ 2- (diajminomethylene) amino] -4-thiazolyl3methyl ]thio]-N- sulfamoylpropionamidine
BL-6341 A
3-[(2-guadinyl-4-thiazolyl)methγlthioethylamino]-4-amino-
1.2.5-thiadiazole monoxide
Ebrotidine p-bromo-N-[[[2-[[[2-[(diaminomethylene)amino]-4- thiazolyl]methyl]thio]ethyl]amino]methylene]benzenesulfonamide
Zaltidine [4-(2-methylimidazol-5-yl)-2-thiazolyl]guanidine
Nizatidine
N-[2-[[[2-[(dimethylamino)methyl]-4- thiazolyl]methyl]thio]ethyl]-N1-methγl-2-nitro-1,1- ethenediamine
Ramixotidine
N-[2-[[[5-[(dimethylamino)methyl3-2-furanyl]methyl]- thio]ethyl]-3-pyridinecarboxamide 1-oxide
BMY-25271
3-amino-4-[2-[(5-dimethylaminomethyl-2-furyl)methylthio]ethylamino]-1 2 5 -thiadiazole 1-oxide
Sufotidine
1-[m-[3-[[1-methyl-3-[(methylsulfonyl)methyl]-1H-1,2,4- triazol-5-yl]amino3propoxy]benzyl]piperidine
Roxatidine
N-[3-[α -piperidino-m-tolyloxy3propy13carbamoylmethyl acetate
BMY - 25368
1-[3-(piperidinomεthyl)phenoxypropγlamino]-2-amino-3,4- dioxocyclobut-1-ene
3[2-[5-(dimethylaininomethyl)-2-furanylmethylthio] ethylamino]thieno[3,4-d]isothiazole 1,1-dioxide
Donetidine
5-(1,2-dihydro-2-oxoρyrid-4-ylmethyl)-2-[2-[s-(dimethylaininomethyl)furan-2-ylmethylthio]-ethylamino]pyrimidin-4(1H)-one
Tiotidine
1-[[2-(diaminomethyleneamino)-thiazole-4-yl]methylthioethyl]-2,3-dimethylguanidine
Oxmetidine
5-(3,4-methylendioxybenzyl)-2-[2-[5-methylimidazole-4- ylmethylthio]ethylamino]-pyrimidine-4(1H)-one
Mitentidine
N-[4(-imidazol-4-yl)-phenyl3-N1-isopropylformamidine
The preferred H2-blocking agents are cimetidine and ranitidine.
Accordingly, the invention relates to
- a method for the prophylactic and therapeutic treatment of each of the ailments above by administering to a host in need thereof of a therapeutically effective amount of a H2-receptor-blocking agent
- a pharmaceutical preparation for use in the prophylactic and therapeutic treatment of each of the ailments above comprising a H2-receptor-blocking agent as active ingredient
- a H2-receptor-blocking agent for use in the manufacture of a medicament for the prophylactic and therapeutic treatment of each of the ailments above. - a method for improving the healing rate of bone fractures by administering to a host in need thereof of an effective amount of a H2-receptor -blocking agent.
Pharmacological tests
Sprague-Dawley male rats (Alab, Stockholm, Sweden) weighing 175-200 g before the tests were used. They obtained a standard diet consisting of rat feed pellets (Alab, Stockholm, Sweden) and tap water. Nine rats were given ranitidine (Hassle, Sweden) 1700 μmol/kg x day, approximately 600 mg/kg body weight per day) via osmotic mini pumps (Alzet 2ML2) which had been implanted subcutaneously. The rats were treated during 26 days and mini pumps were exchanged after 14 days. The pumps were placed under the abdominal skin. Seven rats were used as untreated controls.
45Ca incorporation into the skeleton
2 × 106 cpm 45CaCl2 (Radiochemical Center, Amersham, England) were administered orally by ventricular sond. The rats were killed by tapping blood via abdominal aorta 4 hours after the peroral administration of 45Ca. Radius, sternum, tibia and femur were removed by dissection. Radius and sternum were cleaned, weighed and placed in an oven at 800°C during 24 hours. The ashes were weighed and dissolved in 1M HCl. 10 ml Picofluor-40 (Packard) was added, whereafter the tubes were closed and shaken vigourosly before counting in a Beckman β-counter. Radioimmunoanalysis of gastrin
Serum was prepared at the blood tapping from each rat and gastrin was determined by radioimmunoanalysis (Stadil, F. & Rehfeld, J.F. (1973) Determination of gastrin in Serum. An evaluation of the reliability of a radioimmunoassay. Scan. J. Gastroent. 8, 101-112; Hakansson, R. , Kroesen, J.H. Liedberg, G., Oscarson, J., Rehfeld, J.E.. & Stadil, F. (1974) Correlation between serum gastrin concentration and rat stomach histidine decarboxylase activity, J. Physiol. 243, 483-498).
Operations were performed under ether anaesthesia. Fundectomia, comprising resection of the acid producing part of the ventricle, was performed as has been described in detail by Alumets et al (Alumets, J. , El Munshid, H.A., Hakansson, R., Hedenbro, J., Liedberg, G., Oscarson, J., Rehfeld, J.F., Sundler, F. and Vallgren, S., Gastrin cell proliferation after chronic stimulation. Effects of vagal denervation or gastric surgery in the rat. J. Physiol. 298, 557-569 (1980)). Gastrectomia was prepared by resection of the stomach followed by suturation of eosophagus and duodenum end to end. Operated animals were allowed to recover for one week before treatment with the test substance, as has been described in "Pharmacological tests". The test results are given in Fig. 1 and Fig. 2.
Description of the drawings
Fig.l shows the concentration of gastrin expressed as picogram/ml serum with untreated control rats (average of 7 rats, and with ranitidir-e-treated rats (average of 9 rats) after treatment for 26 days. Fig. 2 shows the amount of radioactive calcium which has been incorporated into the skeleton (radius respectively sternum) expressed in cpm/mg bone ashes. E shows the average of 7 control rats, F shows the average of 9 ranitidine-treated rats, G shows the average of 7 control rats and H shows the average of 9 ranitidine-treated rats.
The continuous lines represent the average of given number of rats and the dashed lines represent the standard error of the average value. The stars designate the significance (i.e. the difference between control and test substance according to Student's t-test p < 0,05 = x; p < 0,01 = xx and p < 0,005 = xxx).
Test results
Ranitidine-treated rats and fundectomized rats developed pronounced and constant hypergastrinemia, which is seen in Fig. 1. The hypergastrinemia which had been developed by treatment with ranitidine stimulated 45Ca-incorporation into the skeleton, which is seen in Fig. 2. Hypergastrinemia caused by fundectomia did not stimulate 45Ca-incorporation into the skeleton.
The tests given above show clearly that treatment with ranitidine led to increased incorporation of calcium into the skeleton. This may be due to hypergastrinemia which in turn via some factor in the acid-producing part of the stomach seems to control the incorporation of calcium into the skeleton.
For clinical use the compounds in known manner are formulated into pharmaceutical formulations for oral, rectal, parεnteral or other mode of administration. Ihε pharmaceutical formulation contains a compound of the invention in combination with a pharmaceutically acceptable carrier. The carrier may be in the form of a solid, semi- solid or liquid diluent, or a capsule. These pharmaceutical preparations are a further object of the invention. Usually the amount of active compounds is between 0.1-95 % by weight of the preparation, between 0.2-20 % by weight in preparations for parenteral use and between 1 and 50 % by weight in preparations for oral administration.
The typical daily dose of the active substance varies within a wide range and will depend on various factors such as for example the individual requirement of each patient, the route of administration and the disease. In general, oral and parenteral dosages will be in the range of 5 to 2000 mg per day of active substance.

Claims

What we claim is:
1. A method for the treatment of osteoporosis by administering to a host in need of such treatment of a therapeutically effective amount of a H2-receptor- blocking compound, optionally together with a pharmaceutically acceptable carrier.
2. A method according to claim 1 where the H2-receptor- blocking compound is cimetidine or ranitidine.
3. A method for the treatment of Paget's disease of bone by administering to a host in need of such treatment of a therapeutically effective amount of a compound as defined in claims 1 or 2, optionally together with a pharmaceutically acceptable carrier.
4. A method for the treatment of primary and secondary hyperparathyroidism by administering to a host in need of such treatment of a therapeutically effective amount of a compound as defined in claims 1 or 2, optionally together with a pharmaceutically acceptable carrier.
5. A method for the treatment of such malignant neoplasms where tumor cells are producing osteoclast-activating factors, by administering to a host in need of such treatment of a therapeutically effective amount of a compound as defined in claims 1 or 2, optionally together with a pharmaceutically acceptable carrier.
6. A metod for the treatment of parodontal diseases, by administering to a host in need of such treatment of a therapeutically effective amount of a compound as defined in claims 1 or 2, optionally together with a pharmaceutically acceptable carrier.
7. A method for the treatment of prostetic and implantrelated bone loss, by administering to a host in need of such treatment of a therapeutically effective amount of a compound as defined in claims 1 or 2, optionally together with a pharmaceutically acceptable carrier.
8 . A method for the treatment of diseases connected with increased bone resorption by administering to a host in need of such treatment of a therapeutically effective amount of a compound as defined in claims 1 or 2, optionally together with a pharmaceutically acceptable carrier.
9. A H2-receptor-blocking compound as defined in claims 1 or 2 for use in the manufacture of a medicament for the treatment of osteoporosis.
10. A H2-receptor-blocking compound as defined in claims 1 or 2 for use in the manufacture of a medicament for the treatment of Paget' s disease of bone.
11. A H2-receptor-blocking compound as defined in claims 1 or 2 for use in the manufacture of a medicament for the treatment of primary and secondary hyperparathyroidism.
12. A H2-receptor-blocking compound as defined in claims 1 or 2 for use in the manufacture of a medicament for the treatment of such malignant neoplasms where tumor cells are producing osteoclast activating factors.
13. A H2-receptor-blocking compound as defined in claims 1 or 2 for use in the manufacture of a medicament for the treatment of parodontal diseases.
14. A H2-receptor-blocking compound as defined in claims 1 or 2 for use in the manufacture of a medicament for the treatment of prostetic and implant-related bone loss.
15. A H2-receptor-blocking compound as defined in claims 1 or 2 for use in the manufacture of a medicament for the treatment of diseases connected with increased bone resorption.
16. A pharmaceutical preparation for use in the treatment of osteoporosis; Paget's disease of bone; primary and secondary hyperparathyroidism; such malignant neoplasms where tumor cells are producing osteoclast-activating factors; such parodontal diseases which are associated with bone loss; or prostetic and implant-related bone loss; and comprising a compound of the formula I as defined in claim 1 as active ingredient.
17. A method for increasing the incorporation of calcium into the skeleton by administering a sufficient amount of a H2-receptor-blocking compound as defined in claims 1 or 2.
18. A H2-receptor-blocking compound as defined in claims 1 or 2 for use in the manufacture of a medicament for the treatment of ailments requiring increased corporation of calcium into the skeleton.
19. A pharmaceutical preparation for use in the treatment of ailments requiring increased incorporation of calcium into the skeleton comprising a H2-receptor-blocking compound as active ingredient.
20. A method for improving the healing rate of bone fractures by administering to a host in need thereof of an affective amount of a H2-receptor-blocking compound, as defined in claims 1 or 2.
21. A H2-receptor-bloσking compound as defined in claims 1 or 2 for use in the manufacture of a medicament for improving the healing rate of bone fractures.
22. A pharmaceutical preparation for use in improving the healing rate of bone fractures, comprising a
H2-receptor-blocking compound as defined in claims 1 or 2 as active ingredient.
EP88910155A 1987-11-13 1988-10-27 New therapeutical use of h 2?-receptor-blocking compounds Withdrawn EP0353262A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8704436 1987-11-13
SE8704436A SE8704436D0 (en) 1987-11-13 1987-11-13 USE OF ANTI-SECRETARY SUBSTANCES FOR NEW INDICATIONS

Publications (1)

Publication Number Publication Date
EP0353262A1 true EP0353262A1 (en) 1990-02-07

Family

ID=20370204

Family Applications (1)

Application Number Title Priority Date Filing Date
EP88910155A Withdrawn EP0353262A1 (en) 1987-11-13 1988-10-27 New therapeutical use of h 2?-receptor-blocking compounds

Country Status (7)

Country Link
EP (1) EP0353262A1 (en)
JP (1) JPH02502188A (en)
AU (1) AU2720388A (en)
DK (1) DK329289A (en)
HU (1) HUT51894A (en)
SE (1) SE8704436D0 (en)
WO (1) WO1989004178A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8629781D0 (en) * 1986-12-12 1987-01-21 Glaxo Group Ltd Pharmaceutical compositions
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
PL195272B1 (en) * 1997-07-22 2007-08-31 Merck & Co Inc Method of inhibiting resorption of bone tissue
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
EP2825159B1 (en) 2012-03-15 2022-06-22 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
ES2860526T3 (en) 2013-07-19 2021-10-05 Boehringer Ingelheim Vetmedica Gmbh Preserved Etherified Cyclodextrin Derivatives Containing A Liquid Aqueous Pharmaceutical Composition
PL2925305T3 (en) 2013-12-04 2017-07-31 Boehringer Ingelheim Vetmedica Gmbh Improved pharmaceutical compositions of pimobendan
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
US4220653A (en) * 1979-01-24 1980-09-02 Vivino A Earl Administration of cimetidine to reduce appetite and facilitate weight loss in persons suffering from excessive weight
US4256743A (en) * 1979-02-22 1981-03-17 President And Fellows Of Harvard College Inhibition of bone resorption with H1 -blocking antihistamines
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
CA1239349A (en) * 1983-10-10 1988-07-19 Eberhard F. Gottwald Pharmaceutical composition containing cimetidine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8904178A1 *

Also Published As

Publication number Publication date
HU886797D0 (en) 1990-05-28
JPH02502188A (en) 1990-07-19
SE8704436D0 (en) 1987-11-13
DK329289D0 (en) 1989-07-03
DK329289A (en) 1989-07-03
WO1989004178A1 (en) 1989-05-18
HUT51894A (en) 1990-06-28
AU2720388A (en) 1989-06-01

Similar Documents

Publication Publication Date Title
Gavras et al. Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor" MK-421".
US7576093B2 (en) Method of treatment of bone-related disorders or conditions
US6221913B1 (en) Dialkyl ureas as calcitonin mimetics
EP0353262A1 (en) New therapeutical use of h 2?-receptor-blocking compounds
KR20040063979A (en) A pharmaceutical composition comprising an effector of dipeptidyl peptidase IV
CZ313597A3 (en) Pharmaceutical preparation
HU203663B (en) Process for producing pharmaceutical composition against osteoporosis containing imidazo(1,2)pyridine derivatives
WO1989003829A1 (en) Omeprazole for treatment of diseases related to bone loss
JP2001302514A (en) Medicament containing phenylethenesulfonamides
JP2618449B2 (en) Drugs for the treatment of alcoholism
US5354773A (en) Use of bafilomycine and derivatives to treat bone diseases
KR100575479B1 (en) Food compositions containing furan derivatives and pharmaceutically acceptable salts thereof for prevention and treatment osteoporosis
KR0147855B1 (en) Osteogenesis promoter
EP0462071A1 (en) Pharmaceutical resorption-improved somatostatin compositions, their preparation and use
HUT56843A (en) Process for producing imidazo(4,5-c)pyridine derivatives and pharmaceutical compositions comprising such compounds as active ingredient
US6060480A (en) Preventives/remedies for muscle tissue degenerations
SPERO et al. Resolution of acromegaly, amenorrhea-galactorrhea syndrome, and hypergastrinemia after resection of jejunal carcinoid
EP0189307A2 (en) Antihistamine-H2 alkyne thiadiazole derivatives
JP2621460B2 (en) Diuretics or antihypertensives
US20050101574A1 (en) Parathyroid hormone production inhibitors containing vitamin d3 derivatives
DK165964B (en) IMPROVED INDOMETHANCIN OR OXICAM BASED ANTI-INFLAMMATORY PREPARATION
KR860000768B1 (en) Substituted preparing substituted furofuranone derivatives
Barton et al. Angiotensin converting enzyme inhibitors. 9. Novel [[N-(1-carboxyl-3-phenylpropyl) amino] acyl] glycine derivatives with diuretic activity
EP0301466B1 (en) Uricosuric composition
DK171222B1 (en) Use of a 2-oxo-imidazolidine compound for the preparation of a pharmaceutical composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19890623

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19910624

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19911105